{
    "references": [
        {
            "bibentry": "(a) Supuran, CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008; 7: 168–81, PMID: 18167490",
            "process_entry": "True",
            "doi": "10.1038/nrd2467",
            "pmid": "18167490",
            "xmlid": "CIT0001"
        },
        {
            "bibentry": "(a) Supuran, CT. Structure-based drug discovery of carbonic anhydrase inhibitors. J Enzyme Inhib Med Chem 2012; 27: 759–72, PMID: 22468747",
            "process_entry": "True",
            "doi": "10.3109/14756366.2012.672983",
            "pmid": "22468747",
            "xmlid": "CIT0002"
        },
        {
            "bibentry": "(a) Supuran, CT. Carbonic anhydrase inhibitors. Bioorg Med Chem Lett 2010; 20: 3467–74, PMID: 20529676",
            "process_entry": "True",
            "doi": "10.1016/j.bmcl.2010.05.009",
            "pmid": "20529676",
            "xmlid": "CIT0003"
        },
        {
            "bibentry": "(a) Pastorekova, S, Parkkila, S, Pastorek, J, Supuran, CT. Carbonic anhydrases: current state of the art, therapeutic applications and future prospects. J Enzyme Inhib Med Chem 2004; 19: 199–229,",
            "process_entry": "True",
            "doi": "10.1517/14728222.2014.991312",
            "pmid": "25495426",
            "xmlid": "CIT0004"
        },
        {
            "bibentry": "(a) Supuran, CT. Carbonic anhydrase inhibitors and activators for novel therapeutic applications. Future Med Chem 2011; 3: 1165–80, PMID: 21806379",
            "process_entry": "True",
            "doi": "10.4155/fmc.11.69",
            "pmid": "21806379",
            "xmlid": "CIT0005"
        },
        {
            "bibentry": "(a) Carta, F, Supuran, CT. Diuretics with carbonic anhydrase inhibitory action: a patent and literature review (2005–2013). Expert Opin Ther Pat 2013; 23: 681–91, PMID: 23488823",
            "process_entry": "True",
            "doi": "10.1517/13543776.2013.780598",
            "pmid": "23488823",
            "xmlid": "CIT0006"
        },
        {
            "bibentry": "Aggarwal, M, Kondeti, B, McKenna, R. Anticonvulsant/antiepileptic carbonic anhydrase inhibitors: a patent review. Expert Opin Ther Pat 2013; 23: 717–24. PMID: 23514045",
            "process_entry": "True",
            "doi": "10.1517/13543776.2013.782394",
            "pmid": "23514045",
            "xmlid": "CIT0007"
        },
        {
            "bibentry": "Kayser, B, Dumont, L, Lysakowski, C, et al. Reappraisal of acetazolamide for the prevention of acute mountain sickness: a systematic review and meta-analysis. High Alt Med Biol 2012; 13: 82–92. PMID: 22724610",
            "process_entry": "True",
            "doi": "10.1089/ham.2011.1084",
            "pmid": "22724610",
            "xmlid": "CIT0008"
        },
        {
            "bibentry": "(a) Masini, E, Carta, F, Scozzafava, A, Supuran, CT. Antiglaucoma carbonic anhydrase inhibitors: a patent review. Expert Opin Ther Pat 2013; 23: 705–16, PMID: 23627893",
            "process_entry": "True",
            "doi": "10.1517/13543776.2013.794788",
            "pmid": "23627893",
            "xmlid": "CIT0009"
        },
        {
            "bibentry": "(a) Fabrizi, F, Mincione, F, Somma, T, et al. A new approach to antiglaucoma drugs: carbonic anhydrase inhibitors with or without NO donating moieties. Mechanism of action and preliminary pharmacology. J Enzyme Inhib Med Chem 2012; 27: 138–47, PMID: 21815773",
            "process_entry": "True",
            "doi": "10.3109/14756366.2011.597749",
            "pmid": "21815773",
            "xmlid": "CIT0010"
        },
        {
            "bibentry": "Chiaramonte, N, Bua, S, Ferraroni, M, et al. 2-Benzylpiperazine: a new scaffold for potent human carbonic anhydrase inhibitors. Synthesis, enzyme inhibition, enantioselectivity, computational and crystallographic studies and in vivo activity for a new class of intraocular pressure lowering agents. Eur J Med Chem 2018; 151: 363–75. PMID: 29635168",
            "process_entry": "True",
            "doi": "10.1016/j.ejmech.2018.04.002",
            "pmid": "29635168",
            "xmlid": "CIT0011"
        },
        {
            "bibentry": "Egan, TJ. Quinoline antimalarials. Expert Opin Ther Pat 2001; 11: 185–209.",
            "process_entry": "True",
            "xmlid": "CIT0012"
        },
        {
            "bibentry": "Sangshetti, JN, Khan, FA, Kulkarni, AA, et al. Antileishmanial drug discovery: comprehensive review of the last 10 years. Rsc Advanc 2015; 5: 32376–415.",
            "process_entry": "True",
            "xmlid": "CIT0013"
        },
        {
            "bibentry": "Keri, RS, Patil, SA. Quinoline: a promising antitubercular target. Biomed Pharmacother 2014; 68: 1161–75. PMID: 25458785",
            "process_entry": "True",
            "doi": "10.1016/j.biopha.2014.10.007",
            "pmid": "25458785",
            "xmlid": "CIT0014"
        },
        {
            "bibentry": "Zajdel, P, Marciniec, K, Maślankiewicz, A, et al. Antidepressant and antipsychotic activity of new quinoline-and isoquinoline-sulfonamide analogs of aripiprazole targeting serotonin 5-HT1A/5-HT2A/5-HT7 and dopamine D2/D3 receptors. Eur J Med Chem 2013; 60: 42–50. PMID: 23279866",
            "process_entry": "True",
            "doi": "10.1016/j.ejmech.2012.11.042",
            "pmid": "23279866",
            "xmlid": "CIT0015"
        },
        {
            "bibentry": "R Solomon, V, Lee, H. Quinoline as a privileged scaffold in cancer drug discovery. Curr Med Chem 2011; 18: 1488–508. PMID: 21428893",
            "process_entry": "True",
            "doi": "10.2174/092986711795328382",
            "pmid": "21428893",
            "xmlid": "CIT0016"
        },
        {
            "bibentry": "(a) Afzal, O, Kumar, S, Haider, MR, et al. A review on anticancer potential of bioactive heterocycle quinolone. Eur J Med Chem 2015; 97: 871–910, PMID: 25073919",
            "process_entry": "True",
            "doi": "10.1016/j.ejmech.2014.07.044",
            "pmid": "25073919",
            "xmlid": "CIT0017"
        },
        {
            "bibentry": "Old, DW, Preparation of alkyl or hydroxyalkyl-1-naphthamide or quinoline derivatives useful in treatment of glaucoma and ocular hypertension patent US Pat. 20150175586A1. 2015.",
            "process_entry": "True",
            "xmlid": "CIT0018"
        },
        {
            "bibentry": "Nainwal, LM, Tasneem, S, Akhtar, W, et al. Green recipes to quinoline: a review. Eur J Med Chem 2019; 164: 121–70. PMID: 30594028",
            "process_entry": "True",
            "doi": "10.1016/j.ejmech.2018.11.026",
            "pmid": "30594028",
            "xmlid": "CIT0019"
        },
        {
            "bibentry": "Chu, XM, Wang, C, Liu, W, et al. Quinoline and quinolone dimers and their biological activities: an overview. Eur J Med Chem 2019; 161: 101–17. PMID: 30343191",
            "process_entry": "True",
            "doi": "10.1016/j.ejmech.2018.10.035",
            "pmid": "30343191",
            "xmlid": "CIT0020"
        },
        {
            "bibentry": "Rivilli, MJL, Turina, AV, Bignante, EA, et al. Synthesis and pharmacological evaluation of pyrazolo [4, 3-c] quinolinones as high affinity GABAA-R ligands and potential anxiolytics. Bioorg Med Chem 2018; 26: 3967–74. PMID: 29954681",
            "process_entry": "True",
            "doi": "10.1016/j.bmc.2018.06.021",
            "pmid": "29954681",
            "xmlid": "CIT0021"
        },
        {
            "bibentry": "Medapi, B, Suryadevara, P, Renuka, J, et al. 4-Aminoquinoline derivatives as novel Mycobacterium tuberculosis GyrB inhibitors: structural optimization, synthesis and biological evaluation. Eur J Med Chem 2015; 103: 1–16. PMID: 26318054",
            "process_entry": "True",
            "doi": "10.1016/j.ejmech.2015.06.032",
            "pmid": "26318054",
            "xmlid": "CIT0022"
        },
        {
            "bibentry": "Lawrence, HR, Kazi, A, Luo, Y, et al. Synthesis and biological evaluation of naphthoquinone analogs as a novel class of proteasome inhibitors. Bioorg Med Chem 2010; 18: 5576–92. PMID: 20621484",
            "process_entry": "True",
            "doi": "10.1016/j.bmc.2010.06.038",
            "pmid": "20621484",
            "pmcid": "PMC3530924",
            "xmlid": "CIT0023"
        },
        {
            "bibentry": "Khalifah, RG. The carbon dioxide hydration activity of carbonic anhydrase I. Stopflow kinetic studies on the native human isoenzymes B and C. J Biol Chem 1971; 246: 2561–73. PMID: 4994926",
            "process_entry": "True",
            "pmid": "4994926",
            "xmlid": "CIT0024"
        },
        {
            "bibentry": "(a) Abo-Ashour, MF, Eldehna, WM, Nocentini, A, et al. Novel hydrazido benzenesulfonamides-isatin conjugates: synthesis, carbonic anhydrase inhibitory activity and molecular modeling studies. Eur J Med Chem 2018; 157: 28–36, PMID: 30071407",
            "process_entry": "True",
            "doi": "10.1016/j.ejmech.2018.07.054",
            "pmid": "30071407",
            "xmlid": "CIT0025"
        },
        {
            "bibentry": "(a) Eldehna, WM, Abo-Ashour, MF, Berrino, E, et al. SLC-0111 enaminone analogs, 3/4-(3-aryl-3-oxopropenyl) aminobenzenesulfonamides, as novel selective subnanomolar inhibitors of the tumor-associated carbonic anhydrase isoform IX. Bioorg Chem 2019; 83: 549–58, PMID: 30471577",
            "process_entry": "True",
            "doi": "10.1016/j.bioorg.2018.11.014",
            "pmid": "30471577",
            "xmlid": "CIT0026"
        },
        {
            "bibentry": "(a) Eldehna, WM, Abo-Ashour, MF, Nocentini, A, et al. Enhancement of the tail hydrophobic interactions within the carbonic anhydrase IX active site via structural extension: design and synthesis of novel N-substituted isatins-SLC-0111 hybrids as carbonic anhydrase inhibitors and antitumor agents. Eur J Med Chem 2019; 162: 147–60, PMID: 30445264",
            "process_entry": "True",
            "doi": "10.1016/j.ejmech.2018.10.068",
            "pmid": "30445264",
            "xmlid": "CIT0027"
        },
        {
            "bibentry": "(a) Eldehna, WM, Nocentini, A, Al-Rashood, ST, et al. Tumor-associated carbonic anhydrase isoform IX and XII inhibitory properties of certain isatin-bearing sulfonamides endowed with in vitro anticancer activity towards colon cancer. Bioorg Med Chem 2018; 81: 425–32,",
            "process_entry": "True",
            "doi": "10.1080/14756366.2017.1316720",
            "pmid": "28537099",
            "pmcid": "PMC6445229",
            "xmlid": "CIT0028"
        },
        {
            "bibentry": "(a) Fares, M, Eladwy, RA, Nocentini, A, et al. Synthesis of bulky-tailed sulfonamides incorporating pyrido[2,3-d][1,2,4]triazolo[4,3-a]pyrimidin-1(5H)-yl) moieties and evaluation of their carbonic anhydrases I, II, IV and IX inhibitory effects. Bioorg Med Chem 2017; 25: 2210–7, PMID: 28256371",
            "process_entry": "True",
            "doi": "10.1016/j.bmc.2017.02.037",
            "pmid": "28256371",
            "xmlid": "CIT0029"
        }
    ],
    "localid": "MED-31411080",
    "doi": "10.1080/14756366.2019.1652282",
    "pmid": "10.1080/14756366.2019.1652282",
    "pmcid": "31411080",
    "curator": "BEE EuropeanPubMedCentralProcessor",
    "source_provider": "Europe PubMed Central",
    "source": "https://www.ebi.ac.uk/europepmc/webservices/rest/31411080/fullTextXML",
    "reference_pointers": [
        [
            {
                "n_rp": 0,
                "xref_id": "CIT0001",
                "rp_string": "1",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),1,142)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 1,
                "xref_id": "CIT0002",
                "rp_string": "2",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),1,142)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 5,
                "xref_id": "CIT0003",
                "rp_string": "3–5",
                "pl_string": "3–5",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[3]",
                "pl_xpath": "/article/body/sec[1]/p[1]/xref[3]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),268,307)",
                "containers_title": [
                    "Introduction"
                ]
            },
            {
                "n_rp": 3,
                "xref_id": "CIT0004",
                "pl_string": "3–5",
                "pl_xpath": "/article/body/sec[1]/p[1]/xref[3]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),268,307)",
                "containers_title": [
                    "Introduction"
                ]
            },
            {
                "n_rp": 4,
                "xref_id": "CIT0005",
                "pl_string": "3–5",
                "pl_xpath": "/article/body/sec[1]/p[1]/xref[3]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),268,307)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 5,
                "xref_id": "CIT0003",
                "rp_string": "3–5",
                "pl_string": "3–5",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[3]",
                "pl_xpath": "/article/body/sec[1]/p[1]/xref[3]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),268,307)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 9,
                "xref_id": "CIT0003",
                "rp_string": "3–5",
                "pl_string": "3–5",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[4]",
                "pl_xpath": "/article/body/sec[1]/p[1]/xref[4]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),659,20)",
                "containers_title": [
                    "Introduction"
                ]
            },
            {
                "n_rp": 7,
                "xref_id": "CIT0004",
                "pl_string": "3–5",
                "pl_xpath": "/article/body/sec[1]/p[1]/xref[4]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),659,20)",
                "containers_title": [
                    "Introduction"
                ]
            },
            {
                "n_rp": 8,
                "xref_id": "CIT0005",
                "pl_string": "3–5",
                "pl_xpath": "/article/body/sec[1]/p[1]/xref[4]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),659,20)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 9,
                "xref_id": "CIT0003",
                "rp_string": "3–5",
                "pl_string": "3–5",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[4]",
                "pl_xpath": "/article/body/sec[1]/p[1]/xref[4]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),659,20)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 13,
                "xref_id": "CIT0003",
                "rp_string": "3–5",
                "pl_string": "3–5",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[5]",
                "pl_xpath": "/article/body/sec[1]/p[1]/xref[5]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),680,322)",
                "containers_title": [
                    "Introduction"
                ]
            },
            {
                "n_rp": 11,
                "xref_id": "CIT0004",
                "pl_string": "3–5",
                "pl_xpath": "/article/body/sec[1]/p[1]/xref[5]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),680,322)",
                "containers_title": [
                    "Introduction"
                ]
            },
            {
                "n_rp": 12,
                "xref_id": "CIT0005",
                "pl_string": "3–5",
                "pl_xpath": "/article/body/sec[1]/p[1]/xref[5]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),680,322)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 13,
                "xref_id": "CIT0003",
                "rp_string": "3–5",
                "pl_string": "3–5",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[5]",
                "pl_xpath": "/article/body/sec[1]/p[1]/xref[5]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),680,322)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 14,
                "xref_id": "CIT0006",
                "rp_string": "6",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),1,363)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Several important pathological consequences result from the dysfunction of hCA II activity, thus this isoform is an established drug target for a multitude of diseases, such as oedema6, epilepsy7, acute mountain sickness8, and glaucoma, where excessive aqueous humour is secreted within the eye, with the subsequent increase in the intraocular pressure (IOP)9–11. CA inhibitors (CAIs) are able to diminish IOP by decreasing the rate of bicarbonate formation and thus secretion of the aqueous humour. For more than 60 years, carbonic anhydrase inhibitors are in clinical use for the treatment of glaucoma, such as the topically acting dorzolamide and brinzolamide drugs, and the systemic acetazolamide and methazolamide drugs9 (Figure 1).",
                "pl_xpath": "/article/body/sec[1]/p[2]"
            },
            {
                "n_rp": 15,
                "xref_id": "CIT0007",
                "rp_string": "7",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),1,363)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Several important pathological consequences result from the dysfunction of hCA II activity, thus this isoform is an established drug target for a multitude of diseases, such as oedema6, epilepsy7, acute mountain sickness8, and glaucoma, where excessive aqueous humour is secreted within the eye, with the subsequent increase in the intraocular pressure (IOP)9–11. CA inhibitors (CAIs) are able to diminish IOP by decreasing the rate of bicarbonate formation and thus secretion of the aqueous humour. For more than 60 years, carbonic anhydrase inhibitors are in clinical use for the treatment of glaucoma, such as the topically acting dorzolamide and brinzolamide drugs, and the systemic acetazolamide and methazolamide drugs9 (Figure 1).",
                "pl_xpath": "/article/body/sec[1]/p[2]"
            },
            {
                "n_rp": 16,
                "xref_id": "CIT0008",
                "rp_string": "8",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[3]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),1,363)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Several important pathological consequences result from the dysfunction of hCA II activity, thus this isoform is an established drug target for a multitude of diseases, such as oedema6, epilepsy7, acute mountain sickness8, and glaucoma, where excessive aqueous humour is secreted within the eye, with the subsequent increase in the intraocular pressure (IOP)9–11. CA inhibitors (CAIs) are able to diminish IOP by decreasing the rate of bicarbonate formation and thus secretion of the aqueous humour. For more than 60 years, carbonic anhydrase inhibitors are in clinical use for the treatment of glaucoma, such as the topically acting dorzolamide and brinzolamide drugs, and the systemic acetazolamide and methazolamide drugs9 (Figure 1).",
                "pl_xpath": "/article/body/sec[1]/p[2]"
            },
            {
                "n_rp": 18,
                "xref_id": "CIT0009",
                "rp_string": "9–11",
                "pl_string": "Several important pathological consequences result from the dysfunction of hCA II activity, thus this isoform is an established drug target for a multitude of diseases, such as oedema6, epilepsy7, acute mountain sickness8, and glaucoma, where excessive aqueous humour is secreted within the eye, with the subsequent increase in the intraocular pressure (IOP)9–11. CA inhibitors (CAIs) are able to diminish IOP by decreasing the rate of bicarbonate formation and thus secretion of the aqueous humour. For more than 60 years, carbonic anhydrase inhibitors are in clinical use for the treatment of glaucoma, such as the topically acting dorzolamide and brinzolamide drugs, and the systemic acetazolamide and methazolamide drugs9 (Figure 1).",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[4]",
                "pl_xpath": "/article/body/sec[1]/p[2]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),1,363)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 18,
                "xref_id": "CIT0009",
                "rp_string": "9–11",
                "pl_string": "Several important pathological consequences result from the dysfunction of hCA II activity, thus this isoform is an established drug target for a multitude of diseases, such as oedema6, epilepsy7, acute mountain sickness8, and glaucoma, where excessive aqueous humour is secreted within the eye, with the subsequent increase in the intraocular pressure (IOP)9–11. CA inhibitors (CAIs) are able to diminish IOP by decreasing the rate of bicarbonate formation and thus secretion of the aqueous humour. For more than 60 years, carbonic anhydrase inhibitors are in clinical use for the treatment of glaucoma, such as the topically acting dorzolamide and brinzolamide drugs, and the systemic acetazolamide and methazolamide drugs9 (Figure 1).",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[4]",
                "pl_xpath": "/article/body/sec[1]/p[2]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),1,363)",
                "containers_title": [
                    "Introduction"
                ]
            },
            {
                "n_rp": 19,
                "xref_id": "CIT0010",
                "pl_string": "9–11",
                "pl_xpath": "/article/body/sec[1]/p[2]/xref[4]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),1,363)",
                "containers_title": [
                    "Introduction"
                ]
            },
            {
                "n_rp": 20,
                "xref_id": "CIT0011",
                "pl_string": "9–11",
                "pl_xpath": "/article/body/sec[1]/p[2]/xref[4]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),1,363)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 21,
                "xref_id": "CIT0009",
                "rp_string": "9",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[5]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),501,237)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 22,
                "xref_id": "CIT0012",
                "rp_string": "12",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),251,175)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Pertaining to its prevalence in diverse natural products, such as alkaloids, and in different pharmacologically active substances, quinoline stands out as a promising privileged scaffold that is endowed with a wide spectrum of biological activities. Just to name a few, antimalarial12, antileishmanial13, anti-tubercular14, antidepressant15, anticancer16,17 and antiglaucoma18 actions were reported for quinoline derivatives. Accordingly, medicinal chemists embarked on exploring various quinoline-based molecules comprehending their potential to develop promising and efficient bioactive compounds19,20. These efforts led to FDA approval for several quinoline-based drugs such as the anticancer agent lenvatinib, the anti-asthmathic drug montelukast, the antiviral Clioquinol, and the anaesthetic Dibucain.",
                "pl_xpath": "/article/body/sec[1]/p[3]"
            },
            {
                "n_rp": 23,
                "xref_id": "CIT0013",
                "rp_string": "13",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),251,175)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Pertaining to its prevalence in diverse natural products, such as alkaloids, and in different pharmacologically active substances, quinoline stands out as a promising privileged scaffold that is endowed with a wide spectrum of biological activities. Just to name a few, antimalarial12, antileishmanial13, anti-tubercular14, antidepressant15, anticancer16,17 and antiglaucoma18 actions were reported for quinoline derivatives. Accordingly, medicinal chemists embarked on exploring various quinoline-based molecules comprehending their potential to develop promising and efficient bioactive compounds19,20. These efforts led to FDA approval for several quinoline-based drugs such as the anticancer agent lenvatinib, the anti-asthmathic drug montelukast, the antiviral Clioquinol, and the anaesthetic Dibucain.",
                "pl_xpath": "/article/body/sec[1]/p[3]"
            },
            {
                "n_rp": 24,
                "xref_id": "CIT0014",
                "rp_string": "14",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[3]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),251,175)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Pertaining to its prevalence in diverse natural products, such as alkaloids, and in different pharmacologically active substances, quinoline stands out as a promising privileged scaffold that is endowed with a wide spectrum of biological activities. Just to name a few, antimalarial12, antileishmanial13, anti-tubercular14, antidepressant15, anticancer16,17 and antiglaucoma18 actions were reported for quinoline derivatives. Accordingly, medicinal chemists embarked on exploring various quinoline-based molecules comprehending their potential to develop promising and efficient bioactive compounds19,20. These efforts led to FDA approval for several quinoline-based drugs such as the anticancer agent lenvatinib, the anti-asthmathic drug montelukast, the antiviral Clioquinol, and the anaesthetic Dibucain.",
                "pl_xpath": "/article/body/sec[1]/p[3]"
            },
            {
                "n_rp": 25,
                "xref_id": "CIT0015",
                "rp_string": "15",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[4]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),251,175)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Pertaining to its prevalence in diverse natural products, such as alkaloids, and in different pharmacologically active substances, quinoline stands out as a promising privileged scaffold that is endowed with a wide spectrum of biological activities. Just to name a few, antimalarial12, antileishmanial13, anti-tubercular14, antidepressant15, anticancer16,17 and antiglaucoma18 actions were reported for quinoline derivatives. Accordingly, medicinal chemists embarked on exploring various quinoline-based molecules comprehending their potential to develop promising and efficient bioactive compounds19,20. These efforts led to FDA approval for several quinoline-based drugs such as the anticancer agent lenvatinib, the anti-asthmathic drug montelukast, the antiviral Clioquinol, and the anaesthetic Dibucain.",
                "pl_xpath": "/article/body/sec[1]/p[3]"
            },
            {
                "n_rp": 26,
                "xref_id": "CIT0016",
                "rp_string": "16",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[5]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),251,175)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Pertaining to its prevalence in diverse natural products, such as alkaloids, and in different pharmacologically active substances, quinoline stands out as a promising privileged scaffold that is endowed with a wide spectrum of biological activities. Just to name a few, antimalarial12, antileishmanial13, anti-tubercular14, antidepressant15, anticancer16,17 and antiglaucoma18 actions were reported for quinoline derivatives. Accordingly, medicinal chemists embarked on exploring various quinoline-based molecules comprehending their potential to develop promising and efficient bioactive compounds19,20. These efforts led to FDA approval for several quinoline-based drugs such as the anticancer agent lenvatinib, the anti-asthmathic drug montelukast, the antiviral Clioquinol, and the anaesthetic Dibucain.",
                "pl_xpath": "/article/body/sec[1]/p[3]"
            },
            {
                "n_rp": 27,
                "xref_id": "CIT0017",
                "rp_string": "17",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[6]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),251,175)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Pertaining to its prevalence in diverse natural products, such as alkaloids, and in different pharmacologically active substances, quinoline stands out as a promising privileged scaffold that is endowed with a wide spectrum of biological activities. Just to name a few, antimalarial12, antileishmanial13, anti-tubercular14, antidepressant15, anticancer16,17 and antiglaucoma18 actions were reported for quinoline derivatives. Accordingly, medicinal chemists embarked on exploring various quinoline-based molecules comprehending their potential to develop promising and efficient bioactive compounds19,20. These efforts led to FDA approval for several quinoline-based drugs such as the anticancer agent lenvatinib, the anti-asthmathic drug montelukast, the antiviral Clioquinol, and the anaesthetic Dibucain.",
                "pl_xpath": "/article/body/sec[1]/p[3]"
            },
            {
                "n_rp": 28,
                "xref_id": "CIT0018",
                "rp_string": "18",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[7]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),251,175)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Pertaining to its prevalence in diverse natural products, such as alkaloids, and in different pharmacologically active substances, quinoline stands out as a promising privileged scaffold that is endowed with a wide spectrum of biological activities. Just to name a few, antimalarial12, antileishmanial13, anti-tubercular14, antidepressant15, anticancer16,17 and antiglaucoma18 actions were reported for quinoline derivatives. Accordingly, medicinal chemists embarked on exploring various quinoline-based molecules comprehending their potential to develop promising and efficient bioactive compounds19,20. These efforts led to FDA approval for several quinoline-based drugs such as the anticancer agent lenvatinib, the anti-asthmathic drug montelukast, the antiviral Clioquinol, and the anaesthetic Dibucain.",
                "pl_xpath": "/article/body/sec[1]/p[3]"
            }
        ],
        [
            {
                "n_rp": 29,
                "xref_id": "CIT0019",
                "rp_string": "19",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[8]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),427,178)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 30,
                "xref_id": "CIT0020",
                "rp_string": "20",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[9]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),427,178)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 33,
                "xref_id": "CIT0021",
                "rp_string": "21–22",
                "pl_string": "21–22",
                "rp_xpath": "/article/body/sec[2]/sec[1]/p/xref[1]",
                "pl_xpath": "/article/body/sec[2]/sec[1]/p/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[2]/sec[1]/p),1635,60)",
                "containers_title": [
                    "Materials and methods",
                    "Chemistry"
                ]
            },
            {
                "n_rp": 32,
                "xref_id": "CIT0022",
                "pl_string": "21–22",
                "pl_xpath": "/article/body/sec[2]/sec[1]/p/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[2]/sec[1]/p),1635,60)",
                "containers_title": [
                    "Materials and methods",
                    "Chemistry"
                ]
            }
        ],
        [
            {
                "n_rp": 33,
                "xref_id": "CIT0021",
                "rp_string": "21–22",
                "pl_string": "21–22",
                "rp_xpath": "/article/body/sec[2]/sec[1]/p/xref[1]",
                "pl_xpath": "/article/body/sec[2]/sec[1]/p/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[2]/sec[1]/p),1635,60)",
                "containers_title": [
                    "Materials and methods",
                    "Chemistry"
                ]
            }
        ],
        [
            {
                "n_rp": 34,
                "xref_id": "CIT0021",
                "rp_string": "21",
                "rp_xpath": "/article/body/sec[2]/sec[2]/p/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[2]/sec[2]/p),257,125)",
                "containers_title": [
                    "Materials and methods",
                    "General procedure for preparation of compounds 4a–f"
                ]
            }
        ],
        [
            {
                "n_rp": 35,
                "xref_id": "CIT0022",
                "rp_string": "22",
                "rp_xpath": "/article/body/sec[2]/sec[2]/p/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[2]/sec[2]/p),257,125)",
                "containers_title": [
                    "Materials and methods",
                    "General procedure for preparation of compounds 4a–f"
                ]
            }
        ],
        [
            {
                "n_rp": 36,
                "xref_id": "CIT0024",
                "rp_string": "24",
                "rp_xpath": "/article/body/sec[2]/sec[11]/p/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[2]/sec[11]/p),1,117)",
                "containers_title": [
                    "Materials and methods",
                    "CA inhibitory assay"
                ]
            }
        ],
        [
            {
                "n_rp": 42,
                "xref_id": "CIT0025",
                "rp_string": "25–29",
                "pl_string": "25–29",
                "rp_xpath": "/article/body/sec[2]/sec[11]/p/xref[2]",
                "pl_xpath": "/article/body/sec[2]/sec[11]/p/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[2]/sec[11]/p),1101,214)",
                "containers_title": [
                    "Materials and methods",
                    "CA inhibitory assay"
                ]
            },
            {
                "n_rp": 38,
                "xref_id": "CIT0026",
                "pl_string": "25–29",
                "pl_xpath": "/article/body/sec[2]/sec[11]/p/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[2]/sec[11]/p),1101,214)",
                "containers_title": [
                    "Materials and methods",
                    "CA inhibitory assay"
                ]
            },
            {
                "n_rp": 39,
                "xref_id": "CIT0027",
                "pl_string": "25–29",
                "pl_xpath": "/article/body/sec[2]/sec[11]/p/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[2]/sec[11]/p),1101,214)",
                "containers_title": [
                    "Materials and methods",
                    "CA inhibitory assay"
                ]
            },
            {
                "n_rp": 40,
                "xref_id": "CIT0028",
                "pl_string": "25–29",
                "pl_xpath": "/article/body/sec[2]/sec[11]/p/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[2]/sec[11]/p),1101,214)",
                "containers_title": [
                    "Materials and methods",
                    "CA inhibitory assay"
                ]
            },
            {
                "n_rp": 41,
                "xref_id": "CIT0029",
                "pl_string": "25–29",
                "pl_xpath": "/article/body/sec[2]/sec[11]/p/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[2]/sec[11]/p),1101,214)",
                "containers_title": [
                    "Materials and methods",
                    "CA inhibitory assay"
                ]
            }
        ],
        [
            {
                "n_rp": 42,
                "xref_id": "CIT0025",
                "rp_string": "25–29",
                "pl_string": "25–29",
                "rp_xpath": "/article/body/sec[2]/sec[11]/p/xref[2]",
                "pl_xpath": "/article/body/sec[2]/sec[11]/p/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[2]/sec[11]/p),1101,214)",
                "containers_title": [
                    "Materials and methods",
                    "CA inhibitory assay"
                ]
            }
        ],
        [
            {
                "n_rp": 43,
                "xref_id": "CIT0013",
                "rp_string": "13",
                "rp_xpath": "/article/body/sec[3]/sec[1]/p[2]/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[1]/p[2]),1,239)",
                "containers_title": [
                    "Results and discussion",
                    "Chemistry"
                ]
            }
        ],
        [
            {
                "n_rp": 44,
                "xref_id": "CIT0024",
                "rp_string": "24",
                "rp_xpath": "/article/body/sec[3]/sec[2]/sec/p/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[2]/sec/p),1,222)",
                "containers_title": [
                    "Results and discussion",
                    "Biological evaluation",
                    "Carbonic anhydrase inhibition"
                ]
            }
        ]
    ]
}